This hub covers seizure first aid: what to do during a seizure, when to use rescue meds, and when to call 911. Clear, research-informed guidance for home, school, sports, and sleep.
Yes, you can get it here! Stick it on the fridge, give it to the grandparents, and share it with teachers.
If a convulsive seizure lasts ~5 minutes, breathing is abnormal, injury occurs, it’s a first seizure, or recovery is not typical.
A written plan for caregivers/schools that includes seizure types, what to do, and when to use rescue meds.
Often yes with 1:1 close supervision, a plan, and risk discussion with your neurologist.
Showers are usually safer than baths. If using a bath, supervision matters.
Researchers studied the use of right vagal nerve stimulation (R-VNS) as a treatment for epilepsy, focusing on patients who had not responded well to other therapies.
This study looked at how effective and safe four different medications—brivaracetam, cenobamate, lacosamide, and perampanel—are for adults with drug-resistant focal epilepsy.
Researchers studied a new treatment called epicranial focal cortex stimulation (eFCS) for people with epilepsy that does not respond to medication.
Researchers looked at clinical trials for adult-type diffuse gliomas, a type of brain tumor, to see how seizures were reported.
A recent study looked at how much teachers know about asthma, type 1 diabetes, and epilepsy in children.
This study looked at the use of MRI-guided laser therapy (MRgLITT) in 88 children and teenagers with various brain conditions, including epilepsy, brain tumors, and cavernous malformations.
This study looked at how the anti-seizure medication levetiracetam affects thyroid function and thyroid size in children with epilepsy.
This study looked at two different surgical treatments for people with nontumoral epilepsy, which is epilepsy not caused by a brain tumor.
Researchers studied the effects of a highly purified form of cannabidiol (CBD), known as Epidiolex® or Epidyolex®, on people with various types of epilepsy, particularly those with developmental and epileptic encephalopathies (DEEs) and complex treatment-resistant epilepsies (TREs).